Terns Pharmaceuticals to Present Positive Clinical Data on NASH Programs at AASLD The Liver … | Business
FOSTER CITY, Calif., October 18, 2021 (GLOBE NEWSWIRE) – Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule candidates for monotherapy and in combination for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that three abstracts detailing clinical data from several non-alcoholic steatohepatitis (NASH) programs within the portfolio of the Company were accepted for presentation at The Liver Meeting® Digital Experience 2021, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), to be held virtually November 12-15, 2021. Oral summaries and posters were published in the Hepatology Supplement, the AASLD’s peer-reviewed journal.
The details of the presentations at the Liver Meeting are as follows:
Title: FXR Liver-Delivered Agonist TERN-101 Demonstrates Favorable Safety and Efficacy Profile in NASH Phase 2a LIFT Study Publication Number: 143 Session Title: Parallel 21: NAFLD and NASH: Clinical Trials of Novel Therapeutics Presenting Author: Rohit Loomba Date and Time: Sunday, November 14, 6:30 p.m. ET
Title: Single doses of the THR-β agonist TERN-501 are well tolerated and result in dose-dependent changes in LDL cholesterol and sex hormone binding globulin in a novel human clinical trial Presentation number: 1889 Session title: NAFLD and NASH: Experimental: Clinical Presenting author: D. Barry Crittenden
Title: Liver-distributed FXR Agonist TERN-101 Leads to Corrected T1 (cT1) Response and a Population Shift to Lower cT1 Risk Categories in NASH Phase 2a LIFT Study Publication Number: 1875 Session Title: NAFLD and NASH: Experimental: Clinical Presenting Author: Eric Lawitz
About TERN-101 TERN-101 is a non-bile acid, liver-distributed FXR agonist that has demonstrated a differentiated tolerance profile and improved target engagement, possibly due to its sustained activation of FXR in the liver. liver, but only its transient activation of FXR in the intestine. FXR is a nuclear receptor primarily expressed in the liver, intestine, and kidneys. FXR regulates the hepatic expression of various genes involved in lipid metabolism, inflammation and fibrosis. Clinical studies with other FXR agonists have shown significant histological improvements in NASH, but have also resulted in pruritus, unwanted lipid changes and discontinuation of treatment. Terns reported the first positive results from the Phase 2a LIFT study of TERN-101 in June 2021.
About TERN-501 TERN-501 is a thyroid hormone receptor (THR-β) beta agonist with high metabolic stability, improved hepatic distribution and greater selectivity for THR-β compared to other THR agonists -β under development. THR-β agonism increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, stimulation of THR-β has the ability to reduce hepatic steatosis and improve serum lipid parameters, especially LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model demonstrated that low doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, liver inflammation and fibrosis. TERN-501 has a high hepatic distribution and is 23 times more selective for activation of THR-β than for activation of THR-α in a cell-free assay, thus minimizing the risk of cardiotoxicity and other side effects. target associated with non-selective THR stimulation. Finally, TERN-501 has been designed to be metabolically stable and is therefore expected to exhibit low pharmacokinetic variability and low clinical dose, making it an attractive candidate for use in fixed dose combinations for the treatment of NASH.
About Terns Pharmaceuticals Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small molecule candidates in monotherapy and in combination for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases . Terns’ portfolio includes three clinical phase development programs, including an FXR agonist, a VAP-1 inhibitor and a THR-β agonist, as well as a preclinical GLP-1 receptor agonist program. Terns is focused on the development of clinically validated, complementary mechanisms of action-based combination therapies to treat the multiple liver disease processes of NASH in order to generate significant clinical benefits for patients. For more information, please visit: www.ternspharma.com.
Caution Regarding Forward-Looking Statements This press release contains forward-looking statements about Terns Pharmaceuticals, Inc. (the “Company”, “we”, “us” or “our”) within the meaning of federal securities laws, including including those related to the Company’s expectations regarding the timing and potential results of clinical trials and other Company development activities, as well as the potential usefulness and progress of the Company’s product candidates in NASH. All statements other than statements of historical fact contained in this press release, including statements regarding the strategy of the Company, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. In some cases, you may identify forward-looking statements by words such as “aim”, “anticipate”, “assume”, “believe”, “contemplate”, “continue”, “could”, “conceive”, “,” “Estimate”, “expect”, “objective”, “intend”, “power”, “objective”, “plan”, “,”, “,”, “of of of” “target” , “Will”, “would” and other similar expressions which are predictions or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements in large part on its current expectations, estimates, forecasts and projections regarding future events and financial trends that it believes could affect its financial condition, results of operations, business strategy and financial needs. In light of the material uncertainties in these forward-looking statements, you should not rely on forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties which could cause actual results and the implementation of the Company’s plans to vary materially, including risks associated with the launch, costs, timing, progress and results of operations. current and future research and development activities of the Company. and preclinical studies and clinical trials. In particular, the impact of the COVID-19 pandemic on the Company’s ability to advance its research, development, manufacturing and regulatory efforts, including the Company’s clinical trials for its product candidates, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing requirements and state business closures -United and in other countries, and the effectiveness of measures taken globally to contain and treat the disease. These risks are not exhaustive. For a detailed discussion of risk factors that could affect the actual results of the Company, please refer to the risk factors identified in the Company’s SEC reports, including, but not limited to, its annual report on Form 10 -K for the fiscal year ended December 31, 2020. and its quarterly reports on form 10-Q for the periods ended March 31, 2021 and June 30, 2021. Unless required by law, the Company does not undertake to publicly update forward-looking statements for any reason.
Contacts for terns
Investors Justin Ng [email protected]
Media Jenna Urban Berry & Company Public Relations [email protected]